[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-365802-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-365802-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","eflornithine-for-the-chemoprevention-of-luminal-gastrointestinal-neoplasms-a-systematic-review","Eflornithine for the Chemoprevention of Luminal Gastrointestinal Neoplasms - A Systematic Review","","Gastrointestinal tract malignancies remain a major global health burden, and chemoprevention is an important strategy to reduce incidence and delay premalignant progression. This systematic review evaluates eflornithine (DFMO), an ornithine decarboxylase inhibitor that suppresses polyamine synthesis, as an alternative to aspirin, which is limited by bleeding risk. Following PRISMA, trials and cohorts in premalignant GI lesions were analyzed. Nine studies met criteria, with limited benefit in phase I–II and promising outcomes in phase III–IV when DFMO was combined with NSAIDs.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/eflornithine-for-the-chemoprevention-of-luminal-gastrointestinal-neoplasms-a-systematic-review/365802/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/eflornithine-for-the-chemoprevention-of-luminal-gastrointestinal-neoplasms-a-systematic-review/365802.png","ImageObject",300,407,{"name":42,"@type":43},"Taylor Morgan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is eflornithine (DFMO) considered for chemoprevention of luminal gastrointestinal neoplasms?","Question",{"text":63,"@type":64},"DFMO inhibits ornithine decarboxylase (ODC), suppressing polyamine synthesis, and has shown promise as an alternative to aspirin in preclinical and limited clinical evidence.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What did the systematic review find about DFMO efficacy in different trial phases?",{"text":68,"@type":64},"Nine studies met inclusion criteria; phase I–II trials involving Barrett’s esophagus and gastric cancer did not report significant benefits, while phase III–IV trials combining DFMO with NSAIDs showed reductions in adenoma recurrence, size, and polyamine levels in high-risk populations.",{"name":70,"@type":61,"acceptedAnswer":71},"What safety issues were reported for DFMO in combination with NSAIDs?",{"text":72,"@type":64},"Side effects included ototoxicity, reversible after discontinuation, and mild gastrointestinal events, occurring at higher doses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},365802,1790297105,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":118,"preview_page_count":33,"preview_urls":144},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review Gastroenterol Res. 2025;18(3):93-100  \nEflornithine for the Chemoprevention of Luminal Gastrointestinal Neoplasms: A Systematic  \nReview  \nAmbar Godoya, Daniela Montalvan-Sanchezb, Fortunato S. Principe-Menesesc, Adrian Riva-Moscosoc, d, Leandro Sierrae, Gloria Erazof, Carlos Avilag, Mirian Ramirez-Rojash, Roberto Gironi, Daniel A. Guifarroj, k  \nAbstract  \nBackground: Gastrointestinal (GI) tract malignancies represent a significant global health burden, being major contributors to cancerrelated morbidity and mortality globally, with over 7.7 million cases reported. While aspirin is a well-studied chemopreventive agent for GI neoplasms, its use may be limited due to the underlying bleeding risk. Eflornithine (DFMO) is an inhibitor of the ornithine decarboxylase (ODC) which inhibits polyamine synthesis, and has shown promise as an alternative chemopreventive agent, particularly in animal studies and limited clinical trials.  \nMethods: Following PRISMA guidelines, we conducted a systematic review of studies evaluating DFMO alone or in combination for chemoprevention in premalignant GI lesions including chronic gastritis, atrophic gastritis, intestinal metaplasia, and dysplasia. The protocol was registered in Prospero (CRD42022309307) . Randomized controlled trials (RCTs) and cohort studies in English or Spanish were included.  \nResults: Nine studies (six RCTs and three phase I-II trials) met inclusion criteria. Phase I-II trials involving Barrett’s esophagus and gas-  \nManuscript submitted January 8, 2025, accepted April 12, 2025  \nPublished online June 4, 2025  \naIndiana University School of Medicine, Department of Medicine, Indianapolis, IN, USA  \nbDepartamento de Medicina Interna, Universidad Nacional Autonoma de Honduras, Tegucigalpa, Honduras  \ncEscuela de Medicina, Universidad Peruana de CienciasAplicadas, Lima, Peru dHospital II-1 Alto Mayo EsSalud, San Martin, Peru  \neDepartment of Medicine, Cleveland Clinic Foundation, Cleveland, OH, USAfTexas Tech University Health Sciences Center, Lubbock, TX, USA gManatee Memorial Hospital, Bradenton, FL, USA  \nhRuth Lilly Medical Library, Indiana University School of Medicine, Indianapolis, IN, USA  \niDepartment of Medicine, University of Nevada Reno, Reno, NV, USA jDepartment of Internal Medicine, John H. Stroger Jr. Hospital of Cook County, Chicago, IL, USA  \nkCorresponding Author: DanielA. Guifarro, Department of Internal Medicine, John H. Stroger Jr. Hospital of Cook County, Chicago, IL, USA. [Email: Daniel.guifarro@cookcountyhealth.org](Email: Daniel.guifarro@cookcountyhealth.org)  \ndoi: [https://doi.org/10.14740/gr1801](https://doi.org/10.14740/gr1801)  \ntric cancer did not report significant benefits. Phase III-IV trials combining DFMO with nonsteroidal anti-inflammatory drugs (NSAIDs) were associated with reductions in adenoma recurrence, size, and polyamine levels in high-risk GI cancer populations. Side effects included ototoxicity, reversible upon discontinuation, and mild GI events, both occurring at higher doses.  \nConclusion: While aspirin remains a frontline chemopreventive agent for GI neoplasms, this review shows that phase III-IV trials suggest promising outcomes in combination with NSAIDs, warranting further investigation. Notably, DFMO’s low cost and favorable toxicity profile may position it as a viable alternative, emphasizing the need for additional RCTs to delineate its efficacy and safety in GI cancer prevention. Further investigation into DFMO’s optimal dosage, duration, and side effect management is essential to establish itas a safe and effective chemopreventive agent.  \nKeywords: Chemoprophylaxis; Gastrointestinal luminal cancer; Eflornithine; DFMO  \nIntroduction  \nGastrointestinal (GI) tract malignancies are an important cause of cancer-related morbidity and mortality worldwide. Colorectal cancers (CRCs) are reported as the second major cause of deaths related to cancer, while stomach cancer is the fourth major cause. In 2020, colorectal, esophag","cbCail0ZNVxEqixA","https://ap.wps.com/l/cbCail0ZNVxEqixA","pdf",1213542,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Keywords\n# Introduction","[{\"question\":\"Why is eflornithine (DFMO) considered for chemoprevention of luminal gastrointestinal neoplasms?\",\"answer\":\"DFMO inhibits ornithine decarboxylase (ODC), suppressing polyamine synthesis, and has shown promise as an alternative to aspirin in preclinical and limited clinical evidence.\"},{\"question\":\"What did the systematic review find about DFMO efficacy in different trial phases?\",\"answer\":\"Nine studies met inclusion criteria; phase I–II trials involving Barrett’s esophagus and gastric cancer did not report significant benefits, while phase III–IV trials combining DFMO with NSAIDs showed reductions in adenoma recurrence, size, and polyamine levels in high-risk populations.\"},{\"question\":\"What safety issues were reported for DFMO in combination with NSAIDs?\",\"answer\":\"Side effects included ototoxicity, reversible after discontinuation, and mild gastrointestinal events, occurring at higher doses.\"}]","Eflornithine for the Chemoprevention of Luminal Gastrointestinal Neoplasms - A Systematic Review | PDF",1790162399,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95a5cef3548686a7a724475ce61547aa.webp",983,1272,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e2334d475abd97e7869db56508a4282.webp",982,1270,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca4b30ee17c3d539223955dee0fa65c1.webp",981,1269,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e332d4ad3c64167f34de7affe9e4915.webp",980,1268]